PURPOSE To evaluate endocrine activity in terms of ovarian function suppression (OFS) of degarelix (a gonadotropin-releasing hormone [GnRH] antagonist) versus triptorelin (a GnRH agonist) in premenopausal patients receiving letrozole as neoadjuvant endocrine therapy for breast cancer.
INTRODUCTION
Ovarian function suppression (OFS) was the first form of systemic treatment for advanced breast cancer. 1 Its use as an adjuvant therapy was associated with improved disease-free and overall survivals in patients younger than age 50 years who had breast cancer. 2 Currently, for premenopausal patients with endocrineresponsive breast cancer, OFS is considered an important aspect of treatment in the advanced disease 3 setting and in the adjuvant and neoadjuvant settings. 4 Gonadotropin-releasing hormone (GnRH) analogs interact with the GnRH receptor and modify release of pituitary gonadotropins. Several GnRH analogs have been developed (eg, triptorelin, goserelin and leuprolide), and there are no apparent differences in their OFS capabilities. 5 Upon administration of GnRH agonists, an initial stimulating action of the hypophysis occurs (flare effect), which eventually causes a sustained decrease in gonadotropin secretion (downregulation) that can be observed after approximately 10 days. For some patients, there can be a delay of 2 to 4 months until downregulation of the gonadotropins occurs. Moreover, approximately 20% of women do not maintain complete OFS with GnRH analogs 6 and experience occasional elevations in estradiol (E2) as a result of sporadic escapes from OFS. Degarelix (Firmagon; Ferring, Copenhagen, DK) is a GnRH antagonist that binds to and blocks GnRH receptors in the pituitary gland, which results in decreased secretion of gonadotropins. In men, this leads directly to a rapid decrease in the production of testosterone, for which suppression to castration levels is achieved within 1 to 3 days and remains sustained during treatment. 7, 8 Degarelix is currently approved for the treatment of prostate cancer. Data are not available for the use of degarelix in patients with breast cancer.
In premenopausal women, suppression of ovarian function with degarelix might be faster than with GnRH analogs and optimally maintained throughout the treatment period. Neoadjuvant endocrine therapy (NET) is an excellent platform for the development of investigational drugs and the exploration of novel combinations that can be developed in other clinical settings. 9 Limited data are available on NET in premenopausal patients. In the Neoadjuvant Anastrozole Versus Tamoxifen in Patients Receiving Goserelin for Premenopausal Breast Cancer (STAGE) trial, 204 premenopausal women were randomly assigned to receive goserelin 3.6 mg/month plus either anastrozole or tamoxifen for 24 weeks before surgery. More patients in the anastrozole group than in the tamoxifen group had a complete or partial response (70.4% v 50.5%, respectively). 10 We therefore designed the TREND (Trial on the Endocrine activity of Neoadjuvant Degarelix) trial (International Breast Cancer Study Group [IBCSG] , an open-label, twoarm, phase II, randomized study, to compare the endocrine activity of triptorelin versus degarelix in premenopausal patients with breast cancer receiving letrozole as NET.
PATIENTS AND METHODS

Patients
Premenopausal women with histologically confirmed stage cT2 to 4b, any nodal stage, M0; estrogen (ER) and progesterone (PgR) receptor expression greater than 50%; human epidermal growth factor receptor 2 (HER2)-negative (by immunohistochemistry and/or in situ hybridization); invasive breast cancer were eligible. Premenopausal status was determined locally as 17-b-estradiol (ie, E2) levels greater than 54 pg/mL (or . 198 pmol/L) measured within 14 days before random assignment. Patients could not have had a prior GnRH analog, a selective ER modulator or aromatase inhibitor (AI) within 12 months before random assignment, or used hormonal treatment (eg, oral, injectable, implanted contraceptive or medicated intrauterine device) in the 2 months before random assignment.
Study Design
Patients were randomly assigned in a 1:1 ratio to receive six 28-day cycles of NET with one of the following: triptorelin 3.75 mg intramuscularly on day 1 of every cycle plus letrozole 2.5 mg/day orally; or degarelix 240 mg subcutaneously given as two subcutaneous injections of 120 mg on day 1 of cycle 1 followed by 80 mg on day 1 of cycles 2 through 6 plus letrozole. Letrozole was started on day 1, concurrent with triptorelin or degarelix. Trial treatments were to start within 14 days of random assignment and could be started at any time during the menstrual cycle. Definitive surgery was performed within 2 to 3 weeks after the last administration of triptorelin or degarelix. After postsurgery evaluation, no additional follow-up data were collected within the trial. Postsurgical treatments were given at the discretion of the investigator. Random assignment was stratified according to age at random assignment (# 39 v $ 40 years).
Study visits occurred before every 28-day cycle for 6 months and required a physical exam, an Eastern Cooperative Oncology Group performance status, weight, and collection of adverse events (AEs; 31 targeted AEs and other grades 3 to 4 AEs according to Common Terminology Criteria for AEs, version 4.0). Tumor evaluation by bilateral mammography and breast ultrasound and laboratory tests (hematology, chemistry, carcinoembryonic antigen [CEA], cancer antigen 15.3 [CA15.3]) were required at baseline, after three cycles, and before surgery. Data about AEs and concomitant medications were also collected 30 days after surgery. Patients completed the 19-item Functional Assessment of Cancer Therapy, endocrine subscale (FACT-ES) at baseline, on day 1 of cycles 2 and 4, and before surgery.
E2, follicle-stimulating hormone (FSH), and luteinizing hormone (LH) levels were determined in a central laboratory from serum samples collected at day 1 of the first treatment cycle before the administration of the first dose (baseline), at 24 and 72 hours, 7 days and 14 days after first injection, and on day 1 of cycles 2 through 6. E2 concentrations were measured by gas chromatography tandem mass spectrometry detection after liquid-liquid extraction. Duplicate standard curves, water blanks, and four assay control pools were processed with samples to assess accuracy and precision of the assay. The lower limit of E2 level quantification was 0.625 pg/mL. Central pathology review of diagnostic biopsy and of the residual surgical specimen was mandatory for this trial, but patients were included on the basis of tumor characteristics as determined by the local pathologist.
The primary end point was time to optimal OFS, calculated as the time from the first injection of degarelix or triptorelin until the first occurrence of a centrally assessed E2 level in the range of optimal OFS (# 2.72 pg/mL or # 10 pmol/L) 11 during the six cycles of NET. Secondary end points included best overall response according to WHO response criteria, 12 rate of node-negative disease at surgery, rate of breast-conserving surgery (BCS), preoperative endocrine prognostic index (PEPI) score, Ki-67 (protein encoded by the MKI67 gene) changes, and patient-reported endocrine symptoms (by FACT-ES summary score). 13 The trial was conducted in three centers in Italy. The IBCSG coordinated the trial and is responsible for the study design, random assignment, collection and management of data, medical review, data analysis, and reporting. The trial was conducted in accordance with the provisions of the Declaration of Helsinki. The ethics committees at each center approved the study protocol, and all patients provided written informed consent. The IBCSG Data and Safety Monitoring Committee reviewed the trial twice yearly. Ferring donated the study drugs.
Statistical Considerations
Analyses were performed according to the intention-to-treat principle. Kaplan-Meier estimates of the cumulative proportions of patients who achieved optimal OFS were calculated. Cox proportional hazards regression and the logrank test, stratified according to age, were used to estimate the hazard ratio, 95% CI, and P value in a comparison of the time to optimal OFS between the two treatment groups.
The statistical design assumed that the cumulative percentages of patients with optimal OFS by 2, 4, 8, 12, and 16 weeks were 30%, 60%, 75%, 90%, and 100% of patients, respectively, assigned to triptorelin plus letrozole and 60%, 95%, 100%, 100%, and 100% of patients, respectively, assigned to degarelix plus letrozole. With 23 patients per group, the study had 90% power to detect a between-group difference in time to optimal OFS using a twosample log-rank test (two-sided a = .05). The calculations were performed using nQuery Advisor (Statistical Solutions Ltd. 8 South Bank Crosse's Green Cork, Ireland) for the logrank test of survival in two groups (simulation with the aforementioned percentages specified). To allow for missing data, the study planned enrollment of 50 patients.
Secondary end points were summarized as the number and percentage of patients or as the median (interquartile range [IQR]) of values by treatment group and/or as between-group differences, and data were reported with CIs. Changes in Ki-67 between pretreatment biopsy and post-treatment surgery were assessed within and between groups using Wilcoxon signed-rank and rank-sum tests, respectively. The analysis of differences in patient-reported FACT-ES summary scores (range, 0 to 76; higher score indicated better function) between treatment groups used linear mixed-effects modeling as a function of postbaseline timepoint and treatment group and controlled for the stratification factors of age (dichotomized as # 39 v $ 40 years) and baseline summary score with an autoregressive covariance structure. For each symptom, the proportion of patients who reported a clinically significant symptom level (responses of "quite a bit'' or ''very much'' a problem) 14 at one or more postbaseline time points was summarized with 90% CIs. The analysis used SAS 9.4 (SAS Institute, Cary, NC), and R version 3.3.1.
RESULTS
Study Population
Between February 24, 2014, and January 10, 2017, 51 patients with ER-positive and PgR-positive (ER and PgR . 50%), HER2-negative, invasive breast cancer were randomly assigned (n = 26 assigned to triptorelin plus letrozole; n = 25 assigned to degarelix plus letrozole; Fig 1) . The median age of the patients was 44 years (IQR, 42 to 49 years; Table 1 ). All patients had an Eastern Cooperative Oncology Group performance status of 0, 49% had clinically node-positive disease, and 90% had a ductal histology.
All patients started and completed six cycles of the assigned trial treatment, with the exception of one patient randomly assigned to degarelix plus letrozole who had surgery after three cycles because of progressive disease. Compliance regarding blood draws over time for the enrolled patients was excellent: 502 (99%) of the 507 blood draws required to assess OFS status over time were obtained.
Endocrine Activity
By the end of the first cycle (29 days), all patients reached optimal OFS. OFS was reached significantly faster among patients assigned to degarelix plus letrozole than among those assigned to triptorelin plus letrozole (median, 3 v 14 days, respectively; hazard ratio, 3.05); optimal OFS was achieved three times faster with degarelix plus letrozole than with triptorelin plus letrozole (95% CI, 1.65 to 5.65; P , .001; Fig 2) . Notably, optimal OFS was maintained for all patients assigned degarelix plus letrozole during subsequent cycles, whereas 15.4% of patients assigned triptorelin plus letrozole had suboptimal OFS (E2 level . 2.72 pg/mL) after cycle 1 (0 events with 119 measurements and six events with 127 measurements, respectively; only. FSH and LH over time are summarized in Figure 4 and Appendix Figures A2, A3, and A4 (online only).
Surgery and Pathology
Forty-nine patients underwent surgery after completion of NET; two patients decided to seek alternative therapies and did not receive surgery within the protocol-suggested time frame. Overall, 38.8% of patients had node-negative disease at surgery ( The median PEPI score at surgery was 6 (IQR, 4 to 7); only one patient (2.0%) had a PEPI score of 0. Ki-67 expression levels were available for all patients on the diagnostic biopsy and for 47 on surgery (excision) samples. Significant reductions in Ki-67 from baseline to surgery were detected within each treatment group (Appendix Fig A5, 
AEs
There were no treatment-related grade 4 AEs in either treatment group, and there were only two grade 3 AEs (hypertension and anemia) in two patients assigned to triptorelin plus letrozole ( Table 3 ). The most common AEs with degarelix plus letrozole versus triptorelin plus letrozole were hot flashes (80.0% v 69.2%), arthralgia (32.0% v 53.8%), insomnia (24.0% v 11.5%), injection site reaction (24.0% v 0%), hypertension (12.0% v 3.8%), and nausea (16.0% v 3.8%).
Patient-Reported Endocrine Symptoms
The FACT-ES completion rates were 88% across assessment time points and were similar between treatment groups. Patients assigned to degarelix plus letrozole reported worse FACT-ES summary scores at each postbaseline time point (Appendix Fig A6, plus-letrozole group and by 11.5% and 15.4%, respectively, of the triptorelin-plus-letrozole group.
DISCUSSION
The results of the TREND trial indicate that, in premenopausal patients treated with letrozole as NET for endocrine-responsive breast cancer, degarelix acted faster than triptorelin to induce optimal OFS. Moreover, degarelix ensured maintenance of optimal OFS in all patients during the subsequent (cycles 2 through 6) treatment period, whereas 15.4% of patients assigned to triptorelin plus letrozole had suboptimal OFS during NET.
These results are consistent with reports of degarelix activity in prostate cancer. 7 In two phase II dose-finding clinical trials, degarelix 240/160 mg and 240/80 mg were shown to effectively suppress testosterone levels in patients with prostate cancer without testosterone surge or inducement of clinical flare. 15, 16 In another trial, both 240/160 mg and 240/80 mg doses were effective and noninferior to leuprolide 7.5 mg in suppression of testosterone. 8 The maintenance of optimal OFS during degarelix therapy might have significant clinical value in the treatment of premenopausal patients with breast cancer not only in the neoadjuvant setting but also in the adjuvant and metastatic settings. In the adjuvant setting, two recently published clinical trials led to a paradigm shift in the endocrine treatment of premenopausal women. The joint analysis of the SOFT (Suppression of Ovarian Function Trial) and TEXT (Tamoxifen and Exemestane Trial) trials showed that the combination of OFS plus exemestane significantly reduced recurrence compared with OFS plus tamoxifen. 17 The combination of OFS plus exemestane is currently recommended for patients at intermediate/high risk of relapse together with adjuvant chemotherapy. 4, 18 Bellet et al 19 reported that, during the first year of exemestane plus triptorelin in the SOFT trial, 17% of the patients had E2 levels greater than the threshold of 2.72 pg/mL (10 pmol/L). Baseline factors related to E2 level greater than 2.72 pg/mL were no prior chemotherapy (P = .06), higher BMI (P = .05), and lower FSH and LH (each P , .01). 19 Other authors reported that approximately 20% of women do not reach complete OFS with LH-releasing hormone analogs plus AIs. 6 This is consistent with our study, in which 15.4% of the patients did not maintain OFS during triptorelin treatment. In our trial, the median age was similar to that described in the SOFT and TEXT trials, but most patients were older than age 40 years and therefore less likely to have ovarian breakthroughs than were younger patients, who showed the greatest benefit from the association of OFS and exemestane in the SOFT and TEXT trials. One could speculate that, in a younger cohort, degarelix could have translated to an even higher percentage of maintained OFS compared with triptorelin. In the presence of incomplete OFS by GnRH analogs, treatment with AIs can stimulate the residual ovarian function and lead to an increase in plasma estrogen levels. 11 Guidelines for the use of adjuvant AIs recommend caution when E2 levels determined by highly sensitive/specific methods such as gas chromatography tandem mass spectrometry detection are more than 10 pmol/L (. 2.72 pg/mL) during treatment with AIs, because this indicates that AIs are not exerting full effectiveness. 11 To our knowledge, this is the first report on the use of degarelix in the treatment of women with breast cancer. The toxicity profile of degarelix was as expected, and no safety signals were identified. Most commonly reported AEs were related to E2 deprivation. The maximum toxicity grade was 2, with the exception of two grade 3 AEs (hypertension and anemia) in two patients assigned to triptorelin plus letrozole. A considerable proportion of patients experienced clinically significant symptom burdens, and higher proportions occurred in patients who received degarelix plus letrozole. The open nature of this study may have affected the AE reports by patients. On the written trial information, a very common ($ 10%) prevalence of hot flushes and injection site AEs was reported for degarelix. Although it is not known how these issues were addressed in the discussion with the patients, it is unlikely that such an effect may explain the different profiles of the patient-reported symptoms. Patients should be made aware of lifestyle interventions and integrative therapies to minimize AEs from endocrine treatment. 20 In this analysis, higher node-negative disease rates and higher BCS rates were observed for patients assigned to degarelix plus letrozole versus triptorelin plus letrozole. These data compare well with results from the literature. In a cohort of premenopausal patients treated with NET, the overall response rate was 50%. 21 Potential limitations of this study are the small number of patients enrolled and the lack of postsurgery follow-up, which did not allow conclusions about the difference in disease outcomes between the treatment groups. In addition, at the time of study design, few similar data were available for breast cancer. The design assumptions of the cumulative optimal OFS rates with triptorelin at time points were based on studies from prostate cancer, 8, 22 and the assumptions appeared to be different from those actually observed. Even so, the comparison depends only on rank data (log-rank test), so the study still has good power to detect a relative difference between treatment arms.
Strengths of our study are adherence to protocol requirements (all patients initiated and completed protocol NET), compliance to trial treatments (most patients received triptorelin/degarelix injections during the hospital visits), and central assessment of E2 levels. The study is hypothesis generating and supports larger studies to assess whether maintenance of OFS with degarelix translates into a better clinical outcome and is worth a trade-off of increased rate of some AEs. Ongoing clinical trials about NET in premenopausal patients are investigating novel associations, 20 and will help identify the best candidates for such treatment as well as possible ways to optimize treatment efficacy.
In conclusion, in premenopausal women receiving letrozole for primary treatment of endocrine-responsive breast cancer, OFS was achieved more quickly and maintained more effectively with degarelix than with triptorelin throughout the NET period. These data support additional studies to assess whether degarelix improves disease control compared with the current standard of care in the treatment of premenopausal patients with breast cancer. 
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